MLEC

Moolec Science SA
CAPPED RATING

Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and pipeline leverage the agronomic efficiency of used target crops, such as soybeans and peas. It operates in the United States, Europe, and South America. The company was founded in 2008 and is based in Luxembourg.

Moolec Science SA (MLEC) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
D-
Factor Score 0.8 / 5.0
Momentum
F
Factor Score 0.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.5
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -88.4%
Price Return 12M -87.0%
Catalyst Signal 0.00
Market Cap $617.2K
TTM Revenue N/A
Price / Sales N/A
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) C+ (2.5) D- (0.8) F (0.5) C+ (2.6) D+ (1.8)
2026-11-06 C+ (2.5) C+ (2.5) D- (0.8) D- (0.8) C+ (2.7) C- (1.9)
2026-10-30 C+ (2.5) C+ (2.5) D- (0.8) D- (0.7) C+ (2.7) D+ (1.8)
2026-10-23 C+ (2.5) C+ (2.5) D- (0.8) D (1.3) C+ (2.6) C- (2.0)
2026-10-16 C+ (2.5) C+ (2.5) D- (0.8) D- (1.1) C+ (2.6) C- (1.9)
Page 1 of 4